These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 2254635)

  • 41. Clinical and causality assessment in herbal hepatotoxicity.
    Teschke R; Schwarzenboeck A; Eickhoff A; Frenzel C; Wolff A; Schulze J
    Expert Opin Drug Saf; 2013 May; 12(3):339-66. PubMed ID: 23458441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Harmonising adverse drug reaction terminology: the role of the Council for International Organizations of Medical Sciences.
    Venulet J; Bankowski Z
    Drug Saf; 1998 Sep; 19(3):165-72. PubMed ID: 9747664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of International Consensus Meeting Criteria for classifying drug-induced liver disorders.
    Bussières JF; Habra M
    Ann Pharmacother; 1995 Sep; 29(9):875-8. PubMed ID: 8547737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug-induced liver injury: A 2-year retrospective study of 1169 hospitalized patients in a single medical center.
    Woo HJ; Kim HY; Choi ES; Cho YH; Kim Y; Lee JH; Jang E
    Phytomedicine; 2015 Dec; 22(13):1201-5. PubMed ID: 26598920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Drug-induced hepatic involvement, something to consider!].
    Oestreicher MK; Desmeules J; Giostra E; Gross B; Hadengue A; Dayer P
    Schweiz Med Wochenschr; 1996 Nov; 126(48):2094-6. PubMed ID: 8992632
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Interstitial pneumopathies: criteria of drug side-effects. Results of consensus meetings].
    Fournier M; Camus P; Benichou C; Danan G; Begaud B; Castot A; Lagier G; Brune J; Pariente R; Chrétien J
    Presse Med; 1989 Sep 2-9; 18(27):1333-6. PubMed ID: 2529493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Causality assessment of herb-induced liver injury using multidisciplinary approach and Roussel Uclaf Causality Assessment Method (RUCAM).
    Nin Chau T; Cheung WI; Ngan T; Lin J; Lee KW; Tat Poon W; Leung VK; Mak T; Tse ML;
    Clin Toxicol (Phila); 2011 Jan; 49(1):34-9. PubMed ID: 21114414
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): causality assessment of 22 spontaneous reports.
    Teschke R; Glass X; Schulze J
    Regul Toxicol Pharmacol; 2011 Dec; 61(3):282-91. PubMed ID: 21893153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Definitions and assessment criteria of acute drug-induced hepatitis. Conclusions of an International Consensus Meeting].
    Danan G
    Gastroenterol Clin Biol; 1991; 15(11):845-8. PubMed ID: 1769475
    [No Abstract]   [Full Text] [Related]  

  • 51. Drug-Induced Liver Injury: An Institutional Case Series and Review of Literature.
    Gayam V; Khalid M; Shrestha B; Hossain MR; Dahal S; Garlapati P; Gill A; Mandal AK; Sangha R
    J Investig Med High Impact Case Rep; 2018; 6():2324709618761754. PubMed ID: 29568780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Carefully reviewing the history of diagnostic scales and paying more attention to the diagnostic value of Roussel - Uclaf causality assessment method scale for drug - induced liver injury].
    Chen CW
    Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):801-803. PubMed ID: 27978922
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug-induced liver injury.
    Abboud G; Kaplowitz N
    Drug Saf; 2007; 30(4):277-94. PubMed ID: 17408305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
    Teschke R; Schulze J; Eickhoff A; Danan G
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Case of Carbamazepine-induced Severe Cholestatic Hepatitis: Case Report and Review of Literature.
    Ganesh S; Shukla L; Kandasamy A; Benegal V
    Indian J Psychol Med; 2017; 39(5):688-690. PubMed ID: 29200572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Toxic liver disease due to drugs, herbs and dietary supplements: diagnostic approaches].
    Teschke R; Schwarzenböck A; Hennermann KH
    Z Gastroenterol; 2007 Feb; 45(2):195-208. PubMed ID: 17304407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introduction of RU 486 in the USA: obstacles and opportunities.
    Thoss E
    Plan Parent Eur; 1993 Oct; 22(3):18-9. PubMed ID: 12288950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
    Woodworth T; Furst DE; Alten R; Bingham CO; Yocum D; Sloan V; Tsuji W; Stevens R; Fries J; Witter J; Johnson K; Lassere M; Brooks P
    J Rheumatol; 2007 Jun; 34(6):1401-14. PubMed ID: 17552067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of two clinical scales for causality assessment in hepatotoxicity.
    Lucena MI; Camargo R; Andrade RJ; Perez-Sanchez CJ; Sanchez De La Cuesta F
    Hepatology; 2001 Jan; 33(1):123-30. PubMed ID: 11124828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liver enzyme abnormalities during concurrent use of herbal and conventional medicines in Korea: a retrospective study.
    Kim NH; Jung HY; Cho SY; Park SU; Park JM; Ko CN
    Phytomedicine; 2011 Nov; 18(14):1208-13. PubMed ID: 21802919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.